Veru Inc
Research Veru Inc (VERU) on Bullrun: market cap USD 46.21M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerVERU
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 46.21M
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 2.74M
- Free cash flow-USD 26.06M
Valuation Snapshot
latest market cap is USD 46.21M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 22.73M | -USD 30.04M | n/a | -2.81 | USD 15.79M | USD 2.98M | USD 18.33M |
| FY2024 | USD 16.89M | -USD 37.80M | -USD 21.84M | 34.7% | -1.65 | USD 24.92M | USD 3.52M | USD 32.32M |
| FY2023 | USD 16.30M | -USD 93.15M | -USD 88.68M | 46.4% | -1.1 | USD 9.63M | USD 14.21M | USD 19.68M |
| FY2022 | USD 39.35M | -USD 84.04M | -USD 48.24M | 77.7% | -1.05 | USD 100.55M | USD 19.82M | USD 82.80M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 46.21M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 31.37M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 95.15M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 105.33M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 425.69M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 471.49M | n/a | n/a | n/a |
About Veru Inc
Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS) in Florida and internationally. It provides FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Veru Inc's market cap?
Veru Inc's market capitalization is USD 46.21M.
What does Veru Inc do?
Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS) in Florida and internationally. It provides FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.